0R1B logo

Biogen LSE:0R1B Stock Report

Last Price

US$158.97

Market Cap

US$23.0b

7D

-0.9%

1Y

-31.2%

Updated

24 Nov, 2024

Data

Company Financials +

0R1B Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More details

0R1B fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Biogen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share PriceUS$158.97
52 Week HighUS$267.36
52 Week LowUS$153.65
Beta-0.061
11 Month Change-13.17%
3 Month Change-22.45%
1 Year Change-31.22%
33 Year Change-34.55%
5 Year Change-47.30%
Change since IPO522.88%

Recent News & Updates

Recent updates

Shareholder Returns

0R1BGB BiotechsGB Market
7D-0.9%0.3%2.2%
1Y-31.2%-18.3%8.0%

Return vs Industry: 0R1B underperformed the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0R1B underperformed the UK Market which returned 8% over the past year.

Price Volatility

Is 0R1B's price volatile compared to industry and market?
0R1B volatility
0R1B Average Weekly Movement2.8%
Biotechs Industry Average Movement9.7%
Market Average Movement4.8%
10% most volatile stocks in GB Market10.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0R1B has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0R1B's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19787,570Chris Viehbacherwww.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
0R1B fundamental statistics
Market capUS$23.01b
Earnings (TTM)US$1.62b
Revenue (TTM)US$9.61b

14.2x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0R1B income statement (TTM)
RevenueUS$9.61b
Cost of RevenueUS$2.35b
Gross ProfitUS$7.26b
Other ExpensesUS$5.65b
EarningsUS$1.62b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.08
Gross Margin75.59%
Net Profit Margin16.81%
Debt/Equity Ratio38.5%

How did 0R1B perform over the long term?

See historical performance and comparison